Copaxone for the Treatment of Percutaneously Accessible Tumors

Inclusion Criteria

• Ability of participant OR legally authorized representative (LAR) to understand this study, and participant or LAR willingness to sign a written informed consent
• Histologically confirmed diagnosis of squamous cell cancer or cutaneous squamous cell cancer or basal cell carcinoma or any malignant tumor that is percutaneously accessible
• One or more tumors measuring at least 5 mm in diameter using standard measuring tape
• Archival tumor tissue consisting of formalin-fixed, paraffin-embedded (FFPE) tumor tissue obtained from standard of care diagnostic biopsy
• No prior therapy for this malignancy
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
• Platelets >= 50 K/UL
• International normalized ratio (INR) less than or equal to 1.5
• Women of child-bearing potential and men with partners of child-bearing potential must agree to practice sexual abstinence, or to use two forms of adequate contraception (hormonal AND barrier method of birth control) prior to study entry, for the duration of study participation until the end of study treatment. If a woman becomes pregnant or suspects she is pregnant while participating in this study, she should inform her treating physician immediately
• Men of child-bearing potential must not father a child or donate sperm while on this study until the end of study treatment

Exclusion Criteria

• Current or anticipated use of other investigational agents while participating in this study
• Psychiatric illness/social situations that would limit compliance with study requirements
• Pregnant or breast feeding. There is a potential for congenital abnormalities and for this regimen to harm breast feeding infants (if applicable) Planned treatment with chemotherapy and/or radiation therapy prior to standard of care surgery. Concurrent treatment with anti-cancer therapy is not allowed
• Lesions in close proximity to vascular structures (i.e., carotid artery or tumors close to other vital organs such as the trachea) would not be considered appropriate for intratumoral injection
• Mucosal lesions only
• Hypersensitivity to copaxone or glatiramer acetate, mannitol, or any component of the formulation
• Any other disease, active, uncontrolled bacterial, viral or fungal infection requiring systemic therapy, metabolic dysfunction, physical examination finding or clinical laboratory finding that leads to reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug, or that may affect the interpretation of the results, or that may render the subject at high risk for treatment complications
• A known condition that leads to immunosuppression such as acquired immune deficiency syndrome (AIDS) or concurrent use of immunosuppressive therapy